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Vascular calciﬁcation is a complex and dynamic process occurring in various physiological
conditions such as aging and exercise or in acquired metabolic disorders like diabetes
or chronic renal insufﬁciency. Arterial calciﬁcations are also observed in several genetic
diseases revealing the important role of unbalanced or defective anti- or pro-calcifying
factors. Pseudoxanthoma elasticum (PXE) is an inherited disease (OMIM 264800)
characterized by elastic ﬁber fragmentation and calciﬁcation in various soft conjunctive
tissues including the skin, eyes, and arterial media. The PXE disease results from
mutations in the ABCC6 gene, encoding an ATP-binding cassette transporter primarily
expressed in the liver, kidneys suggesting that it is a prototypic metabolic soft-tissue
calcifying disease of genetic origin. The clinical expression of the PXE arterial disease is
characterized by an increased risk for coronary (myocardial infarction), cerebral (aneurysm
and stroke), and lower limb peripheral artery disease. However, the structural and functional
changes in the arterial wall induced by PXE are still unexplained. The use of a recombinant
mouse model inactivated for the Abcc6 gene is an important tool for the understanding
of the PXE pathophysiology although the vascular impact in this model remains limited
to date. Overlapping of the PXE phenotype with other inherited calcifying diseases could
bring important informations to our comprehension of the PXE disease.
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ARTERIAL CALCIFICATION IS AN INDEPENDENT RISK
FACTOR OF CARDIOVASCULAR DISEASES
Arterial calciﬁcation is gaining an increasing interest as an inde-
pendent marker for cardiovascular (CV) diseases in acquired
metabolic diseases, such as type II diabetes (Becker et al., 2008)
and chronic renal insufﬁciency (Goodman et al., 2000). Vascular
calciﬁcation increases physiologically with age and studies from
Egyptian mummies have revealed that arterial calciﬁcation is not
a feature of modern life style due to the absence of risk factors such
as smoking, high fat cholesterol diets encountered in these ancient
civilizations (Allam et al., 2011).
Calciﬁcation of the intimal layers can complicate atheroscle-
rotic plaques favoring the risk of rupture whereas deposit within
themedial layer contributes to stiffen arterialwall leading to hyper-
tension, cardiac hypertrophy, and heart failure (Demer andTintut,
2008). Similarly to the bone, ectopic calcium sediment within the
arterial wall is a dynamic and tightly regulated biological pro-
cess involving a large number of cytokines and cellular pathways
(Giachelli, 2004; Persy and D’Haese, 2009). Contrary to the bones,
the artery is a tubular organ that should remain soft and ﬂexi-
ble but resilient to the high distending blood pressure. The elastic
properties of the arterial wall plays a key role in damping the cyclic
pressure changes produced by the beating heart (O’Rourke et al.,
2002). This dampening effect predominates within the large elas-
tic vessels such as aorta and progressively decreases downstream as
the vessel wall becomes more muscular in the medium and small-
sized arteries allowing a continuous ﬂow and to protect the thin
walled capillaries against high pressures. Therefore, any changes
in arterial wall elasticity, i.e., the recoiling force, and distensibility,
(the capacity to be distended), either physiologically with aging
(so called arteriosclerosis) or in response to abnormal metabolic
conditions such as type II diabetes or chronic renal insufﬁciency,
contribute to stiffen the arterial wall. Stiffening of the arterial
wall will reduce the dampening effect leading to the increase in
systemic arterial pressure, mainly pulse pressure, and ultimately
damage the small capillaries in end-organs such as brain, kidneys,
or heart (Laurent et al., 2009).
Our understanding of the direct or indirect contribution of
calciﬁcation in the vascular system remains limited due to themul-
tifactorial mechanisms. Although both elastic lamina and medial
calciﬁcation could share similar genetic determinants, whether or
not calciﬁcation precedes or follows the disruption and/or the
degeneration of the elastic ﬁbers is often difﬁcult to establish
(Wang et al., 2009). The resulting elasto-calcinosis refers to a timely
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and well-balanced interaction between several local and remote
factors (see review Atkinson, 2008). The mechanisms underly-
ing calciﬁcation of the elastic ﬁbers are multifactorial including
physico-chemical conditions, inﬂammation and oxydative stress,
metabolic dysfunction, and unbalanced promoters/inhibitors of
calciﬁcation. This process can occur focally in the intimal layer
and may complicate atheromatous plaques whereas it occurs more
diffusely in the media.
The role of genetics in the calciﬁcation process is likely to take
an important place since than >40% of the variance of aortic and
coronary calciﬁcation phenotype could be under the control of
genes. The roles of genes have been deciphered in various mono-
genic diseases but also in the general population (O’Donnell et al.,
2002; Assimes et al., 2008; Rampersaud et al., 2008) and have been
recently reviewed by Rutsch et al. (2011).
The pathophysiology of calciﬁcation in metabolic diseases is of
a particular concern and the present review will focus mainly on
pseudoxanthoma elasticum (PXE), an inherited disease displaying
speciﬁc and unusual characteristics that belongs to a larger group
of genetically and metabolically determined calcifying vascular
diseases.
PSEUDOXANTHOMA ELASTICUM: AN ENIGMATIC
CALCIFYING GENETIC DISEASE
Pseudoxanthoma elasticum is an inherited autosomal recessive
multisystem disorder affecting connective tissues. Its phenotypic
expression is characterized by the fragmentation and mineraliza-
tion of elastic ﬁbers in the skin termed elastorrhexis, the Bruch’s
membrane of the retina and the vasculature (Neldner, 1988; Hu
et al., 2003; Uitto et al., 2011). Its prevalence is estimated from
1/25,000 to 1/50,000 and the causativemutations have been identi-
ﬁed in the ABCC6 gene encoding a trans-membrane ATP-binding
cassette transporter, subfamily C, member 6 (ABCC6/MRP6; Le
Saux et al., 2000) that is primarily expressed in the liver and the
kidney, but with much lower expression in other affected tissues
such as skin, eyes, or arteries (Kool et al., 1999). The biologi-
cal function of the ABCC6 transporter and its substrates remains
totally unknown to date. The phenotype seems to result from
an unknown defect originating from the liver and the kidney
leading to the extracellular calcium sediment but probably intra-
cellular (Martin et al., 2012). Several studies have demonstrated
that normal tissues exposed to the serum from PXE patients
or mice knockout for Abcc6 are able to calcify (Le Saux et al.,
2006; Jiang et al., 2007, 2010). Therefore, PXE is considered as a
prototypical metabolic calcifying disease of genetic origin (Jiang
and Uitto, 2006). PXE is also characterized by its delayed onset
and a variability in its phenotypic expression suggesting that a
large number of co-factors contribute to its phenotype. The clas-
sical risk factors involved in arteriosclerosis, such as tobacco,
hypertension, dyslipidemia, could be greatly suspected to inter-
fere with the severity of the vascular expression of the disease,
although most of the vascular complications in PXE occur later
during the life (>40 years) than the skin and eyes lesions, with
an unexplained female preponderance (Uitto et al., 2010). The
2/3 female–1/3 male ratio in PXE leads to an unusual and unex-
plained prevalence of arterial disease in female compared to the
general population. A PXE-like phenotype has also been reported
in other genetic diseases such as beta-thalassemia and sickle cell
anemia (Fabbri et al., 2009), cutis laxa (Vanakker et al., 2007),
generalized arterial calciﬁcation in infancy (Kalal et al., 2012),
a defect in gamma-glutamyl carboxylase (Vanakker et al., 2007),
familial idiopathic basal ganglia (Wang et al., 2012) and more
rarely induced by pharmacological substances such as seen with
D penicillamine (Ratnavel and Norris, 1994). The fact that PXE
phenotype could overlap with other genetic diseases suggests that
these diseases share a common pathophysiology (Nitschke et al.,
2012). The main phenotypical differences reported in the liter-
ature between the genetic calcifying diseases are summarized in
Table 1.
A number of candidate substrates for ABCC6 have been
hypothesized. The observation that PXE patients exhibit a low
plasma vitamin K level and that anti-vitamin K drugs accelerate
calciﬁcation in normal and in Abcc6−/− mice (Li et al., 2012)
raised the hypothesis for a role of vitamin K in the calciﬁcation
process. Vitamin K is a key factor for the activation of tissue calci-
ﬁcation inhibitor factors such as matrix Gla proteins (MGPs). This
hypothesis has not been conﬁrmed due to no changes in the cal-
ciﬁcation process occurring in PXE animal models supplemented
with vitamin K (Brampton et al., 2011; Fülöp et al., 2011; Gorgels
et al., 2011). The implication of adenosine as a calcifying factor
in PXE has also been hypothesized (Markello et al., 2011), as well
as oxidative stress (Pasquali-Ronchetti et al., 2006; Zarbock et al.,
2007), although the role of oxidative stress has not been evidenced
by endothelial dysfunction at present in PXE.
THE VASCULAR LESIONS AND HISTOLOGICAL FINDINGS
IN PXE
The elementary arterial lesions observed in PXE are characterized
by mineralization of the elastic ﬁbers of the medial layer, pre-
dominantly within the medium and small-sized musculo-elastic
arteries. Abnormal elastic ﬁbers are thought to be produced by
the PXE skin ﬁbroblasts (Quaglino et al., 2000), but could also
occur with normal ﬁbroblasts in the presence of PXE serum (Le
Saux et al., 2006) or in presence of elastin degradation products
(Simionescu et al., 2005). These ﬁndings suggest that PXE is a
disorder of the mechanisms controlling the production of matrix
constituents and that elastic ﬁber mineralization is caused by fac-
tors abnormally produced and entrapped within the ﬁber during
elastin ﬁbrogenesis (Baccarani-Contri et al., 1994). These ﬁnding
called for the “elastosis hypothesis” as the primary mechanism
in PXE and that calciﬁcation is secondary. A primary role for
smooth muscle cells and ﬁbroblasts in PXE is suspected as they
are a source of many regulatory proteins involved in the calciﬁ-
cation process such as alkaline phosphatase and MGP (Shanahan
et al., 1999; Simionescu et al., 2005). Finally, an abnormal bal-
ance between elevated proteolysis activitywith increasedP-selectin
(Gotting et al., 2008), matrix metallo-proteinase (MMP) 2 and
9 (Diekmann et al., 2009), suggests an abnormal remodeling
of the extra cellular matrix (ECM) in PXE. Despite unknown
mechanism sequence for elastosis and calciﬁcation, the nature
and affected sites of calciﬁcation lead to different functional
expression.
The macroscopic distribution of the calciﬁcation along the
arterial tree can be mapped using standard X-ray, although 3D
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Table 1 | Comparative characteristics of the arterial phenotype in PXE and other related disorders.
Beta-thalassemia/
Sickle cell disease
PXE-like + cutis laxa PXE GACI ACDC
(or CALJA)
Elementary arterial phenotype
Intima-media thickness Increased Unknown Increased
Endothelial dysfunction Defective Unknown Unknown Unknown Unknown
Stenosis Yes (26.7% mostly
cerebral)
Yes (PAD 50%) Yes (mostly coronary
and cerebral)
Yes (mostly coronary,
cerebral, and renal)
Dilatation/aneurysm Sporadic Yes (mostly cerebral) Infrequent Popliteal
Calciﬁcation Present Present Present Present Present
Arterial malformations gastrointestinal, eyes
(neovascularization) and carotids (?)
Coagulation defects Present (50%) Present Secondary? Present Present
Defective gene HBB/HBF GGCX ABCC6 ENPP1 NT5E
For each disorder, bibliographical references for vascular phenotype are indicated. GACI, generalized arterial calciﬁcation of infancy (Rutsch et al., 2001; Kalal et al.,
2012); ACDC, arterial calciﬁcation or CALJA, calciﬁcation of joints and arteries due to deﬁciency of CD73 (Markello et al., 2011); HBB/HBF, hemoglobinopathies Beta
and S (Aessopos et al., 1998; Fabbri et al., 2009; Musallam et al., 2011); GGCX, gamma-glutamyl carboxylase (Vanakker et al., 2007, 2011; Li et al., 2009a); ABCC6,
adenosine triphosphate-binding cassette (ABC) gene subfamily C (Boutouyrie et al., 2001; Germain et al., 2003; Kornet et al., 2004; Leftheriotis et al., 2011; Kupetsky-
Rincon et al., 2012); ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase (Mackenzie et al., 2012; Nitschke et al., 2012); NT5E, Ecto-5′-nucleotidase (Markello
et al., 2011; St. Hilaire et al., 2011).
reconstruction using helicoidal X-rays scans provides a more
precise quantiﬁcation and site identiﬁcation (see Figure 1). In
our experience, calciﬁcation accumulates mostly within the distal
superﬁcial femoral and below-knee arteries (tibialis and pedalis),
a distribution mostly observed in the arteriosclerotic process asso-
ciated with aging. Skin lesions are extensively documented in
PXE, as skin biopsy are routinely done for diagnosis. However,
histologic ﬁndings of the PXE-related vascular lesion are sparse
and obtained from rare available autopsy samples. Ultrastructural
analysis from the ascending aorta, iliac arteries, and vena cava from
2 males with PXE (36 and 80 years old), revealed that veins and
arteries were similarly damaged (Gheduzzi et al., 2003). The alter-
ations were not distributed homogeneously along the vessels with
spotty alterations of elastic ﬁbers, and aggregates of thin strands
of amorphous elastin. The von Kossa staining revealed calcium
sediment within the medial layers of the arterial wall of medium
(e.g., carotids)- or small (radial)-sized arteries. In carotids, calci-
ﬁcation was found extracellularly around elastin ﬁbers although
slight increase in intracellular calcium is also observed. Elastic
ﬁbers appears fragmented and proteoglycans accumulated prefer-
entially within the media rather than intima compared to controls
(Kornet et al., 2004). Qualitative andquantitative alteration in pro-
teoglycans metabolism have been reported with increased heparin
sulfate and decreased chondroitin sulfate in patient’s urine (Mac-
cari et al., 2003).
FUNCTIONAL CHANGES IN PXE ARTERY
The functional impacts of the arterial lesions, represented by
elasto-calcinosis and proteoglycans accumulation, have been
examined in a limited number of studies. Most of our knowledge
is derived from non-invasive structural and dynamic observa-
tions using ultrasound techniques in living subjects and have
provided important data for the understanding of the arterial
lesions in PXE and their clinical expression. Three functional
studies involving a small number (≈25) of PXE patients have
focused on the carotid artery, an easily accessible large-sized
musculo-elastic artery (Boutouyrie et al., 2001; Germain et al.,
2003; Kornet et al., 2004). One of these studies has reported
changes in the radial artery, a medium-sized muscular artery and
the aorta, the main large-sized elastic artery of the body (Germain
et al., 2003).
INCREASED INTIMA MEDIA THICKNESS
An increased carotid intima media thickness (IMT) has been
reported in two human studies (Germain et al., 2003; Kornet
et al., 2004) and another more recently involving mice (Kupetsky-
Rincon et al., 2012). Compared to age and gender-matched
patients, these changes were more marked in older patients than
in younger ones under the age of 40. An increased carotid IMT is
independently associated with a higher risk for CV events which
could represent a relevant argument to explain an accelerated
arteriosclerosis in PXE with higher than normal CV incidents
(Eigenbrodt et al., 2008). This increase in IMT was not associ-
ated with an enlargement of the lumen size and was responsible
for a 19% increase in the arterial wall mass. By contrast, the radial
arteries exhibited a smaller lumen with a thicker IMT, suggesting
an inward remodeling (Germain et al., 2003).
The larger IMT seems to result from the higher amount of
proteoglycans without proliferative change in the vascular smooth
muscle cells (VSMC). Proliferation of theVSMC toward the lumen
leads to arterial stenosis and occlusion, and is observed in response
to an abnormal mechano-transductive signaling in elastin deﬁ-
ciency diseases, such as Williams–Beuren syndrome (Li et al.,
1998). But this may not be the sole mechanism since a higher
IMT with a progressive loss of VSMC has also been reported
in Progeria (Gerhard-Herman et al., 2011). More complex
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FIGURE 1 | Anterior and posterior 3D-views of lower limb arterial
calcification in pseudoxanthoma elasticum revealed with helicoidal
X-ray tomodensitometry. Calciﬁcation in the femoral artery is tagged in
green, the popliteal in purple, and the visible distal arteries are tagged in
blue. Note the absence of calciﬁcations within the middle popliteal
segment.
changes have also been reported with multilayered aspects in
PXE coronary (Miwa et al., 2004) or mammary arteries (Sarraj
et al., 1999).
Although these conclusions remain to be conﬁrmed in larger
cohorts, the arterial remodeling in PXE peripheral arteries exhibits
differences from other arterial remodeling such as aging, hyper-
tension, and atherosclerosis. This remodeling is characterized by
intima-media thickening predominantly in the large andmedium-
sized musculo-elastic arteries (Boutouyrie et al., 1992). Aging is
also deﬁned by an outward remodeling whereas hypertension and
atherosclerosis are rather characterized by an inward remodel-
ing. This remodeling is variable along the arterial tree (Bortolotto
et al., 1999; Bjarnegard and Länne, 2010) and with gender, women
exhibiting a higher wall/lumen ratio than men (Green et al., 2010).
The use of imaging techniques with higher spatial resolution will
be very helpful to conﬁrm and discriminate the relative changes of
thickness between the intimal and medial layers, and between the
different vascular beds.
Arterialwall stiffness and elasticity inPXEarteries: It is expected
that both fragmentation of elastic ﬁbers and calciﬁcationwill affect
the arterial elasticity of the PXE arteries.
Compared to age and sex-matched controls, the distensibil-
ity was found either unchanged (Germain et al., 2003) or higher
(Kornet et al., 2004) in the large-sized artery, such as carotid, and
in medium-sized arteries such as radial (Germain et al., 2003).
Furthermore, in the older female patients, the elastic modu-
lus was found unchanged in small-sized but was higher in the
medium-sized artery. A lower or unchanged compressibility of
the small-sized arterial wall was also reported in the ankle arteries
of PXE patients (Leftheriotis et al., 2011).
Therefore, it is likely that the complex rearrangement of the
extracellular matrix in PXE arterial wall resulting from the com-
bination of elastin fragmentation associated to proteoglycans
replacement, focal accumulation of calcium and activated MMP
(Zarbock et al., 2010) in the media could mask a predicted arterial
stiffness.
CLINICAL EXPRESSION OF THE VASCULAR PXE PHENOTYPE
The keystone clinical manifestations in PXE are represented by
visual impairment due to the loss of central vision, large skin
folds of esthetic concern, and CV complications (Neldner, 1988;
Uitto et al., 2011). The vascular lesion in PXE takes a major
place in the complications and the clinical outcome. Although,
it seems that the lifespan of these patients is relatively pre-
served despite no clear reports on this point, the vascular impact
of the disease is crucial and will be detailed in the following
paragraphs.
ARTERIAL HYPERTENSION
Since the earliest reports, the presence of an arterial hyper-
tension in PXE has been controversial with a highly variable
prevalence reported in the literature ranging from 8% (Neldner,
1988) and up to 25% of the patients (Gotting et al., 2005). Even
for the highest range, this reported prevalence remains within
the overall limits of hypertension estimated to be 26.4% of the
world’s population (Kearney et al., 2005). In PXE, a higher than
normal prevalence was likely explained on the basis of a renal
artery stenosis or increased arterial stiffness resulting from the
elasto-calcinosis (Goodman et al., 1963). A higher serum xylosyl-
transferase (XT-1), a ﬁbrosismarker of the extracellularmatrixwas
found in hypertensive PXE patients (Gotting et al., 2005), though
this is not supported by functional data (cf paragraph above).
The association between ABCC6 and angiotensin polymorphisms
(T174M and M235T) was not demonstrated in hypertensive
PXE compared to normals (Gotting et al., 2005). Therefore, the
higher prevalence of arterial hypertension in PXE remains to be
demonstrated.
ANEURYSMS AND DISSECTIONS
An abnormally dilated and/or ruptured arterial wall is the most
life-threatening complication of the PXE disease. Contrary to
other genetic diseases where the connective tissues are affected,
as in Marfan’s or Elhers–Danlos diseases, reports of aneurysm in
PXE patients are sparse and almost anecdotic.
In the cerebral vasculature, the prevalence of intracranial
aneurysms is difﬁcult to estimate. A Belgian PXE cohort (n = 100)
based on self-reported data concluded that it was an unrelated
association (van den Berg et al., 2000) while the association
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between intracranial malformations, including aneurysms, and
PXE may not be fortuitous (Vasseur et al., 2011).
Aneurysms in the other vascular beds such as aorta or lower
limbs are very rarely reported. ABCC6 mutations were found
in a minority of non-PXE patients (5/133) with abdominal aor-
tic aneurysms (Schulz et al., 2005), but this was not statistically
signiﬁcantly different from healthy controls and could not be
considered as a genetic risk factor for aortic aneurysms. Aorto-
coronary aneurysm has also been reported (Heno et al., 1998)
but seems not speciﬁc to PXE as it has also been reported in
other PXE-like syndromes, such as beta-thalassemia (Farmakis
et al., 2004). Common genetic factors underlie medial calciﬁ-
cation, such as ABCC6 and aneurysm development, suggesting
that although medial disruption and calciﬁcation may occur in
parallel, medial disruption does not strictly occur as a result
of vascular calciﬁcation (Wang et al., 2009). The possibility for
a higher prevalence for arterial dissection, such as the sponta-
neous disruption of the internal layers of an artery, common
in the carotids of PXE, is still under discussion (Brandt et al.,
2005), but remains anecdotic at present. Although severalmissense
mutations (H623Q, R3190W, and R1268Q) were found in the
patients with carotid dissection, these mutations were not disease-
causing as they were also detected in healthy subjects (Morcher
et al., 2003).
ISCHEMIC STROKE
Beside the risk of stroke due to cerebral hemorrhage with rup-
tured intracranial aneurysms, the risk of ischemic stroke (IS) is
another feared complication in PXE but remains difﬁcult to estab-
lish. IS was reported in 15% of the PXE patients from a cohort
of 38 patients compared to the general population (0.3–0.5%;
Vanakker et al., 2008). In a cohort of 100 patients, IS was reported
in seven patients with one patient having recurrent IS leading to
a relative risk of 3.6 (95% conﬁdence interval 3.3–4.0) of ISs in
patients under 65 years (van den Berg et al., 2000). Focal cere-
bral ischemia in PXE was predominantly caused by small-vessel
occlusive disease. Atherosclerotic plaques could co-exist with PXE
lesions, but results from our cohort (unpublished data) showed
that carotid plaques were absent in 55/93 (59.1%), unilateral in
17/93 (18.3%), and bilateral in 21/93 (22.6%) compared to age
and gender-matched controls (p = 0.987) suggesting that it is not a
primarymechanism for stroke in PXE. Transient cerebral ischemic
attack could result from intermittent hemodynamic cerebral
insufﬁciency due to intracranial arterial malformation (Vasseur
et al., 2011).
CARDIAC DISEASES
Cardiac diseases in PXE are mainly represented by myocardial
infarction, angina pectoris, and valvular malfunction (Neldner,
1988; Vanakker et al., 2008). Data from the largest cohorts (Neld-
ner, 1988; Vanakker et al., 2008) have reported symptoms of
myocardial origin ranging from 13 to 15% for angina pectoris
but lower for infarction (1–5%) of the patients occurring at
age <55 years and sometimes causing death. In the coronary
arterial bed, the association with a heterozygous R1141X muta-
tion in ABCC6 and ischemic vascular events including stroke,
was not demonstrated in the general population (n = 66831
participants; Hornstrup et al., 2011), although a strong associa-
tion was reported only with coronary artery disease (Koblos et al.,
2010). Additionally, Abcc6 deﬁciency was found to increase infarct
size and apoptosis in amouse cardiac ischemia–reperfusionmodel,
although there were no differences in cardiac calciﬁcation fol-
lowing ischemia/reperfusion (Mungrue et al., 2012). Abnormal
coronary wall suggests that speciﬁc structural factors are likely
present in these vascular beds (Miwa et al., 2004). Interestingly,
the transferability of the PXE phenotype, i.e., calciﬁcation, to the
arterial graft is still questioned (Sarraj et al., 1999; Iliopoulos et al.,
2002; Song et al., 2004).
PERIPHERAL ARTERIAL DISEASE
Contrary to the other arterial beds, an early and severe periph-
eral arterial disease (PAD) described as a slowly worsening lower
limb claudication is consistently and extensively reported in PXE
patients without obvious CV risk factors. PAD is detected clin-
ically by absence of ankle pulse, and the presence/absence of
symptoms of a lower limb claudication such as a calf pain that
limits or interrupts a walk. Additionally, the severity of PAD
can be objectively determined by measuring the ankle-brachial
systolic pressure index (ABI) which corresponds to the ratio of
the systolic ankle and brachial pressures that normally ranges
from 0.9 to 1.39, and the treadmill walking distance with the
help of transcutaneous PO2 (Abraham et al., 2003). The preva-
lence of lower limb claudication, the symptomatic expression of
PAD, is very high in PXE (53% in the Belgian cohort Vanakker
et al., 2008 and 42% in ours) (Leftheriotis et al., 2011), a pro-
portion clearly higher than the 9% men and 5% women with
PAD reported in the general population. By contrast, the treadmill
test, an objective evaluation of the arterial claudication, showed
that only 56% of PXE with an ABI <0.90 were symptomatic
during the test. The discrepancy between a high proportion of
PAD detected by ABI with relatively less symptoms of inter-
mittent claudication suggests that the PAD is well compensated
by an efﬁcient collateral circulation in PXE. This tolerance to
ischemia was further demonstrated in our cohort by relatively
well-preserved tissue oxygenation in PXE patients during walking.
Interestingly, a relatively high incidence of subclinical peripheral
artery disease (41%) was also reported in the carrier popula-
tion (n = 21) suggesting that PAD could represent a frequent
clinical manifestation, even in heterozygous patients. In addi-
tion to the presence/absence of ankle artery pulse, the ABI is a
validated diagnostic tool for the detection of PAD and estima-
tion of its severity, mainly in the asymptomatic patient (Diehm
et al., 2009). PAD is also an independent marker of atheroscle-
rosis associated with higher rates of CV diseases in the general
population (Golomb et al., 2006). Calciﬁcations in the tunica
media of PXE patients are expected to increase arterial stiffness
and thus decrease arterial wall compressibility (Kim et al., 2012).
Although calciﬁcationpredominates in the small-sized ankle arter-
ies, the preserved arterial compressibility in these arteries remains
unexplained.
HEMORRHAGE
Hemorrhages are a frequent ophthalmologic complication in PXE
due to the rupture of proliferative choroidal neovascularization
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secondary to angioid streak. To a lesser extent, gastrointestinal
hemorrhage have also been reported and represent a life-
threatening condition in PXE. The mechanism of hemorrhage
remains unknown, but suggests sub-mucosal arterial malforma-
tions fragilized by the medial calciﬁcation with risk of rupture
likely to the Bruch’s membrane in the eyes. Neovessels and/or mal-
formation could also result fromdefective regulatory pathways and
vascular endothelial growth factor (VEGF) gene polymorphisms
such as the c.-460T and the c.674C alleles that are indepen-
dent risk factors for development of severe retinopathy (Zarbock
et al., 2009). The genetic deﬁciency gamma-glutamyl carboxylase
(GGCX), which is a PXE-like syndrome associated with an abnor-
mal production of coagulation factors, are more prone to severe
uncontrol bleeding (Li et al., 2009a).
WHAT DOES PXE MODELS TEACH US ABOUT
CARDIOVASCULAR DISEASES?
Similar to other genetic diseases, the use of genetically engineered
organisms such as mouse or zebraﬁsh (Danio rerio) is helpful
in our understanding of the PXE pathophysiology. Abcc6−/−
mice exhibit a low-to-mild level of medial arterial calciﬁcations
(Gorgels et al., 2005; Klement et al., 2005), although most cal-
ciﬁcation processes develop markedly in speciﬁc organs such as
the vibrissae, and represents an interesting marker of peripheral
calciﬁcation (Le Corre et al., 2012). Other mouse strains such
as C3H/HeOuJ are spontaneously prone to soft connective tis-
sues calciﬁcation, due to the defective function of Abcc6, that
can be easily followed and quantiﬁed using X-rays (Le Corre
et al., 2012). Finally, the zebraﬁsh model exhibits severe abnor-
mal development that were fully rescued by co-injection of mouse
Abcc6 mRNA (Li et al., 2010). Although the mechanism of the
arterial lesions in PXE remains unexplained, the fact that exte-
riorized tissue lesions develop remotely from the predominant
sites of ABCC6 demonstrates that modifying factors are at play
and limits our conclusions from these mouse models. There is
now a constellation of data arguing for the concomitant role of
modifying genes (Li et al., 2007; Hendig et al., 2008), polymor-
phisms (Schon et al., 2006) and mutations, regulatory pathways
(Martin et al., 2011) as well as nutritional and environmental
factors (Zarbock et al., 2007, 2009, 2010; Pisciotta et al., 2009)
considerably widening the phenotypic expression and severity of
the disease. Furthermore, the selective involvement of anatom-
ical sites such as skin, eyes, arteries is usually explained by the
presence of elastic ﬁbers (with the exception of the lungs), but
recent data suggests that collagen ﬁbers could also be involved
(Gorgels et al., 2012).
THERAPEUTIC ISSUES IN THE PXE ARTERIAL DISEASE
In absence of validated and speciﬁc therapeutic targets in PXE,
the treatment of arteriopathy remains limited. Vitamin K was
not proven as an efﬁcient treatment, although no data are
presently available in human but the lack of a consistent result in
proof-of-concept studies conducted in mice are not encouraging
(Gorgels et al., 2011; Jiang et al., 2012). Despite disappointing
initial results from a pilot study conducted in humans (Yoo
et al., 2012), attempt to reduce calciﬁcation using phosphate
binder (LaRusso et al., 2009) or magnesium supplementation
has recently gained renewed interest with conclusive results in
Abcc6−/− mice (LaRusso et al., 2009; Li et al., 2009b; Kupetsky-
Rincon et al., 2012). Treatment of acute ischemic complications
is sporadically reported in the literature without obvious differ-
ence compared to the general population, although reports of
limb amputation in the literature have never been made to our
knowledge.
Finally, the careful management of CV risk factors remains
an important point since atheroma could mask pre-existing
lesions. Factors that could aggravate arterial calciﬁcation should
be avoided in these patients such as anti-vitamin K which is an
oral anticoagulant drug known to favor calciﬁcation (Price et al.,
1998) that can now be advantageously replaced by anti-Xa oral
therapy after the hemorrhage risk/beneﬁt balance has been prop-
erly evaluated. The question of preventive anti-platelet therapy for
IS is unsolved at present. In the general population, anti-platelet
treatment such as aspirin is advised for secondary prevention of IS,
but the higher prevalence of upper gastrointestinal hemorrhages
in PXE remains a ﬁrm contraindication for the use of aspirin as
well as for anticoagulants. A major challenge for all clinical trials
attempted in PXE is the need for an objective and reproducible
quantiﬁcation of the soft-tissue calciﬁcation. In this way, quan-
tiﬁcation of the arterial calciﬁcation could be an interesting tool
complementary to skinbiopsyorultrasound imaging andophthal-
mologic follow-up since the severity of cutaneous manifestations
and angioid streak of PXE are likely predictive of CV involvement
(Utani et al., 2010).
In conclusion, although the arterial remodeling observed in
PXE shares some of the features of arteriosclerosis and other
calcifying vascular diseases of metabolic origin, it is not readily
comparable to atherosclerosis. This raises challenging questions
on the central role of the hepato-renal axis in the soft-tissue
calcifying processes and PXE represents a prototypical systemic
metabolic disease of genetic origin. The severity of the disease
is progressive and highly variable in which CV symptoms and
PAD seems a constant ﬁnding in these patients. Furthermore, the
higher than expected compressibility of the arterial wall may rep-
resent a useful marker as well as quantiﬁcation of the arterial
calcium load. Data from larger cohorts are awaited with more
detailed phenotypic descriptions. From a clinical point of view,
the absence of efﬁcient therapy, the follow-up of these patients
ﬁrst requires a tight control and management of the usual CV risk
factors in addition to the limitation of pro-calcifying factors. The
place of other anti-calcifying drugs, such as denosumab remains
unknown at present. Finally a comparative analysis of the overlap-
ping phenotypes such as PXE, generalized arterial calciﬁcation of
infancy (GACI), and other PXE-like diseases is likely to add valu-
able information on the elusive mechanism of calcifying genetic
diseases.
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